StockData
Xencor Inc logo

Xencor Inc (XNCR) stock

XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)

Close on Nov 18, 2026Market cap $2.56BP/E –Yield –

Xencor total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xencor's total debt was $104.90M at Jun 30, 2026. For fiscal 2025 it was $119.75M, down 26.8% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$119.75M-26.8%
FY2024Dec 31, 2024$163.61M-13.7%
FY2023Dec 31, 2023$189.48M–
FY2022Dec 31, 2022$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$104.90M-27.7%
Q1 FY2026Mar 31, 2026$108.53M-29.7%
Q4 FY2025Dec 31, 2025$119.75M-26.8%
Q3 FY2025Sep 30, 2025$133.14M-23.0%
Q2 FY2025Jun 30, 2025$145.02M-19.3%
Q1 FY2025Mar 31, 2025$154.38M-16.6%
Q4 FY2024Dec 31, 2024$163.61M-13.7%
Q3 FY2024Sep 30, 2024$172.80M–
Q2 FY2024Jun 30, 2024$179.76M–
Q1 FY2024Mar 31, 2024$185.10M–
Q4 FY2023Dec 31, 2023$189.48M–
Q4 FY2022Dec 31, 2022$0–

More Xencor figures

See a number that looks wrong?